ArticleGastroenterology2023

Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine.

Zhigang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.